ASSESSment of Perfusion, Oxygen Saturation, Endothelial Function and Coagulation in Circulatory SHOCK (ASSESS-SHOCK)

March 19, 2024 updated by: Erika Wilkman, MD PhD, Helsinki University Central Hospital

ASSESSment of Peripheral Perfusion, Tissue Oxygen Saturation, Endothelial Function and Coagulation Disorder in Circulatory SHOCK, the ASSESS - SHOCK Study

The objective of the observational cohort study is (1) to deduce whether measurements of peripheral near-infrared spectroscopy (NIRS) (lower limb) associate with the development of organ dysfunction as assessed by daily Sequential Orfgan Failure Score (SOFA) in the Intensive Care Unit (ICU), (2)whether cerebral (frontal) tissue haemoglobin oxygen saturation (StO2) values are associated with delirium in the ICU and (3) the association of frontal and peripheral StO2 with other micro- and macrohemodynamic parameters in this patient group , (4) to deduce the associations between shock, endotheliopathy, disseminated intravascular coagulation (DIC) and tissue perfusion and, last, the feasibility of central and peripheral NIRS monitoring in shock patients in the ICU using the Medtronic INVOS NIRS StO2 appliances. In addition, the investigators target to evaluate (5) the incidence, evolution, and outcome of sepsis-associated DIC, and (6) the associations between a) continuous hemodynamic data, b) laboratory data (such as syndecan-1 (SDC-1), vascular adhesion protein 1 (VAP1), CD73, heparin binding protein (HBP), endostatin, chromogranin, mitochondrial function tests,blood count d-dimer, international normalized ratio (INR), neuron specific enolase and metabolomics data) (7) and study associations of singlenucleotide polymorphisms with developing organ dysfunction and 90-day mortality. To compare the hemodynamic alterations of burn patients to septic patients with the intention to find new ways to monitor and manage hemodynamic and particularly microcirculation in burn patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background:

Circulatory shock is a frequent condition in the intensive care unit, comprising roughly one of three patients in the intensive care unit (ICU), and associated with high mortality rates. Current treatment guidelines state that one of the main goals for therapeutic interventions is to improve tissue perfusion to prevent subsequent organ dysfunction and death. In acute critical illness, up to one fourth of the patients develop severe hemostatic aberrations and coagulopathy, called disseminated intravascular coagulation (DIC), which is associated with excess mortality.

Despite differences in the underlying cause, acutely critically ill patients share similar features that may be driven by shock. This response, potentially escalating to life-threatening conditions, is relatively homogenous. The shock induced sympatho-adrenal hyperactivation may be a critical driver this endotheliopathy. If allowed to proceed uncontrollably, damages to the microcirculation and organ dysfunction may follow.

Near-infrared spectroscopy (NIRS), a non-invasive method based on the principles of light transmission and absorption, offers a non-invasive and continuous bedside method to assess tissue haemoglobin oxygen saturation (StO2), which may serve as an indirect measure of the adequacy of tissue perfusion. NIRS could potentially be used for early identification of patients with tissue hypoperfusion and therefore high risk of developing organ dysfunction, and may also be used for assessing frontal cerebral oxygen saturation in circulatory failure and its use is well documented in general anaesthesia in many patient groups. There are some data showing an association between low frontal StO2 values and delirium in the ICU. The use of near-infrared spectroscopy to measure tissue oxygenation in healthy humans has been well validated. However, assessing tissue oxygenation using NIRS in critically ill patients is less well established. The hemodynamic and other systemic responses in burns are similar to those in septic shock. However, the mechanisms behind these responses have not been compared between burn and septic shock patients to our knowledge. Overall, the knowledge of microcirculation and how to monitor it in burn patients is limited.

Objectives:

The objective of the observational cohort study is (1) to deduce whether measurements of peripheral NIRS (lower limb registered proximal of the knee cap) associate with the development of organ dysfunction as assessed by daily sequential organ failure assessment score (SOFA) in the ICU during days 1 to 7 in the ICU, (2) whether cerebral (frontal) StO2 values are associated with delirium in the ICU and (3) the association of frontal and peripheral StO2 with other micro- and macrohemodynamic parameters in this patient group , (4) to deduce the associations between shock, endotheliopathy, DIC and tissue perfusion and, last, the feasibility of central and peripheral NIRS monitoring in shock patients in the ICU using the INVOS tm NIRS StO2 appliances. In addition, the investigators target to evaluate (5) the incidence, evolution, and outcome of sepsis-associated disseminated intravascular coagulation (DIC), and (6) the associations between a) continuous hemodynamic data, b) laboratory data (such as syndecan-1 (SDC-1), vascular adhesion protein 1 (VAP1), CD73, heparin binding protein (HBP), endostatin, chromogranin, mitochondrial function tests, blood count d-dimer, INR, neuron specific enolase and metabolomics data) (7) and study associations of singlenucleotide polymorphisms with developing organ dysfunction and 90-day mortality. To compare the hemodynamic alterations of burn patients to septic patients with the intention to find new ways to monitor and manage hemodynamic and particularly microcirculation in burn patients.

Design:

Observational multi-center study

Patient population:

Patients with circulatory shock admitted to the intensive care units (ICU) fulfilling the inclusion criteria.

Sample size:

A minimum of 250patients with circulatory shock with NIRS registration A minimum of 400 patients with sepsis for evaluation of incidence of DIC and metabolomics and genetic tests (genome-wide association study, GWAS)

Methods:

Patients with circulatory shock admitted to the intensive care unit (ICU) fulfilling the inclusion criteria but none of the exclusion criteria within 4 hours of vasopressor inititation in the ICU and signs of clinical hypoperfusion or elevated lactate levels. Frontal and peripheral NIRS StO2 registration is performed using the Medtronic INVOS appliances and bilateral central and peripheral sensors for 48 hours from study inclusion. The INVOS NIRS registration is blinded and cannot be used for clinical decision making. The frontal and peripheral StO2 registrations will be collected for further analyses. Blood samples will be taken from an arterial cannula at inclusion, and at 12 h, 24h and 48h, blood gas samples will be drawn every 2 hours. Data on demographic data, health status, chronic illnesses and medications prior to ICU admission will be collected during the study. Hemodynamic data, information on vasopressor and inotrope medication, need and use of sedatives, fluid balance and specific ICU interventions during the ICU stay will also be collected, as well as daily intensive care delirium screening checklist (ICDSC) and SOFA-score registrations. An electronic case report form (CRF) will be used in the study. In addition to clinical data, data of feasibility and reported problems considering the use of NIRS StO2 registrations will be collected. Blood samples will be frozen and stored locally for further processing and analyses.

Study Type

Observational

Enrollment (Actual)

325

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Helsinki, Finland, 00029
        • Helsinki University Hospital
      • Kuopio, Finland, 70029 KYS
        • Kuopio University Hospital
      • Tampere, Finland, 33521 Tampere
        • Tampere University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population will comprise 400 critically ill patients with circulatory shock from 4 university hospitals during approximately 2 years between April 2019 and December 2021. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.

Description

Inclusion Criteria:

Age ≥ 18 Critically ill patients requiring Intensive Care Unit (ICU) care with circulatory shock within 4 hours (≤ hours) of ICU admission or with circulatory shock developing in the ICU within 24 hours from ICU admission and within 4 hours of initiation of vasopressor treatment presenting with the below listed signs of for circulatory shock

  1. Hypotension - need for vasopressor to achieve mean arterial pressure (MAP) ≥65 mmHg after 1L of crystalloid solution

    and

  2. Any sign of hypoperfusion (at least one of the signs below)

    • blood lactate ≥2 mmol/L
    • mottling score ≥ 2
    • Base Excess (BE) ≤ - 5 mEq/L
    • prolonged capillary refill time ≥ 2 s
    • cool periphery beyond elbows or knees bilaterally
    • altered mentation

    OR

    Confirmed or suspected infection and anti-microbial treatment

    OR as an independent criteria for the ASSESS-SHOCK BURNS substudy

  3. Burn injury ≥30% total body surface area(TBSA), ICU admission within 12h of the injury, with or without hypotension and signs of hypoperfusion within 4 hours of ICU admission

Exclusion Criteria:

  • Age < 18 years
  • Pregnant or lactating
  • Known refusal to any clinical study or this specific study
  • Consent not obtained (according to local regulatory statements for ethical conduct of research)
  • Out-of-hospital cardiac arrest (OHCA) patients
  • Terminal illness and not considered for full intensive care support
  • Planned postoperative admission
  • Postoperative intensive care after organ transplantation
  • Patients who are likely to be transferred to the ward in 24 hours
  • Defects of skin, underlying tissues or extremities preventing the use of the central or peripheral NIRS probes (the first 250 enrolled patients)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Circulatory failure / NIRS monitoring
Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit (ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the (near-infrared spectroscopy) NIRS-substudy.
Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
Circulatory Failure / no NIRS monitoring
Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
Gut dysbiosis, delirium and long term cognition

ASSESS-shock participants that have been treated at Meilahti ICU:s and survived the ICU admission to discharge, who are living in the Helsinki and Uusimaa Hospital District area or reasonable traveling distance to the unit for cognitive testing.

Cognitive function testing is performed after ICU discharge and at 3 and 6 months after ICU discharge. Testing of the microbiome is performed by collecting and analyzing fecal samples at ICU admission and at 7 days after ICU admission.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in severity of Organ dysfunction during the first week in ICU (study period)
Time Frame: At 7 days in ICU
Change in the total Sequential Organ Failure Assessment (SOFA) score from day 1 to day 7 in the ICU, higher SOFA score indicates greater severity of organ failure, the total SOFA score ranges from 0-24 points
At 7 days in ICU
Average severity of Organ dysfunction during the first 7 days in the ICU (study period)
Time Frame: First week in the Intensive Care Unit after admission
Average Sequential Organ Failure Assessment (SOFA) during days 1 to day 7 in the ICU, higher SOFA score indicates greater severity of organ failure, the total SOFA score ranges from 0-24 points
First week in the Intensive Care Unit after admission
New organ dysfunctions
Time Frame: First week in the Intensive Care Unit after admission
Number of new organ dysfunctions (new organ dysfunction defined as one of 6 SOFA subscores ≥3 points/ total 4 points, higher points indicate greater severity. Only one new organ dysfunction / each subscore can be used for calculation of total number of new organ dysfunctions in one week
First week in the Intensive Care Unit after admission
90-day mortality
Time Frame: 90 days
Death within 90 days from ICU admission
90 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
28-day mortality
Time Frame: 28 days
28-day mortality
28 days
ICU length of stay
Time Frame: 90 days
ICU length of stay
90 days
Intensive care delirium incidence
Time Frame: First week in the Intensive Care Unit after admission
Delirium diagnosis in the ICU assessed by Intensive Care Delirium Scoring Checklist (ICDSC) scoring during days 1-7 defined as ICDSC score value of four points or more ( total score: 0-8 points)
First week in the Intensive Care Unit after admission
Intensive care delirium severity
Time Frame: First week in the Intensive Care Unit after admission
Number of Intensive Care Delirium Scoring Checklist (ICDSC) scores (assessment performed twice daily) of ≥4 points indicating presence of delirium during days 1-7
First week in the Intensive Care Unit after admission
Intensive care delirium scoring checklist aggregate and average score during first week in intensive care
Time Frame: First week in the Intensive Care Unit after admission
Aggregate Intensive Care Delirium Scoring Checklist (ICDSC) scores during days 1-7 . Total score ranges from 0 to 8 points. The aggregate score of all daily ICDSC measurements ( sum of all daily scores performed twice daily) will be divided by number of measurements to adjust for possible differences in number of measurements (= average ICDSC score)
First week in the Intensive Care Unit after admission
INVOS NIRS feasibility and safety questionnaire
Time Frame: 0-48 hours in Intensive Care Unit after enrolment into study
Feasibility of frontal and peripheral near-infrared spectroscopy tissue (NIRS) haemoglobin oxygen saturation (StO2) assessment in circulatory shock during the 48 h registration. Feasibility and registration issues are assessed using a questionnaire. Feasibility will be assessed every eight hours ( during each nurse's shift assessing feasibility and saefty on a scale from 0 to 5. Higher score indicatesmore severe feasibility issues
0-48 hours in Intensive Care Unit after enrolment into study
Time to Extubation
Time Frame: 28 days
Time to extubation
28 days
Days off ventilator in 28 days
Time Frame: 28 days
Days off ventilator in 28 days
28 days
Days without vasoactive medication in 28 days
Time Frame: 28 days
Days without vasopressor or inotropic medication
28 days
Days without RRT in 28 days
Time Frame: 28 days
Days without renal replacement therapy of any kind in 28 days
28 days
Cognitive dysfunction after ICU discharge
Time Frame: 6 months
Cognitive dysfunction assessed by a set of neuropsychological tests
6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycocalyx and endothelial injury biomarkers such as: Syndecan-1 (SDC-1), vascular adhesion protein 1 (VAP1), CD73, heparin binding protein (HBP), angiopoietin-2, endostatin, chromogranin
Time Frame: First week in the Intensive Care Unit after admission
Injury of the endothelium and glycocalyx
First week in the Intensive Care Unit after admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Erika Wilkman, MD, PhD, Helsinki University Central Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2019

Primary Completion (Actual)

June 30, 2023

Study Completion (Actual)

October 31, 2023

Study Registration Dates

First Submitted

January 15, 2019

First Submitted That Met QC Criteria

January 18, 2019

First Posted (Actual)

January 24, 2019

Study Record Updates

Last Update Posted (Actual)

March 21, 2024

Last Update Submitted That Met QC Criteria

March 19, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HUS/420/2018

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Circulatory Failure

Clinical Trials on NIRS monitoring

3
Subscribe